TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01617577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF; filgrastim
Description: The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
Study: NCT00913107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal®
Description: The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegretol®
Description: The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegretol®
Description: The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days.
Study: NCT01138683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrafiltration
Description: Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diuretics
Description: Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
Study: NCT02004704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402665
Description: Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion
Study: NCT02675543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitreous Tamponade with Silicone Oil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitreous Tamponade with Silicone Oil
Study: NCT03382366

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling, risk of fall evaluation, and MR acquisition.
Description: Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling, risk of fall evaluation, and MR acquisition.
Description: Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
Study: NCT01347788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Cabozantinib PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Cabozantinib PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Cabozantinib PO QD
Study: NCT00505609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Days Method
Description: The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
Study: NCT05137756

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01158365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID (Dermacid)
Description: Route of administration: local

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LACTIC ACID (Dermacid)
Description: Route of administration: local

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerine Vegetal Soap Granado Traditional
Description: Route of administration: local

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine Vegetal Soap Granado Traditional
Description: Route of administration: local
Study: NCT02619123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored screening according to breast density
Description: Different interval of mammography screening according to breast density

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annual invitation to mammography
Description: Annual interval mammography screening according to international guidelines for women younger than 50 years old
Study: NCT00479622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: Arm 1 = 800 mg Arm 2 = 2000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: Arm 1 = 800 mg Arm 2 = 2000 mg
Study: NCT01286038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
Study: NCT01831427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Andecaliximab
Description: Placebo to match andecaliximab administered by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Andecaliximab
Description: Placebo to match andecaliximab administered by IV infusion
Study: NCT04033406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2482
Description: VIR-2482 given by intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by intramuscular injection
Study: NCT03999359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Metacognitive Therapy
Description: Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
Study: NCT03984955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate with mannitol (Ostenil Tendon)
Description: 1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma Injection
Description: Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Subcutaneous sham injection
Description: Sham injection will penetrate the skin, but no therapeutic substance will be injected
Study: NCT04704271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled THC
Description: 4 mg inhaled THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo (no active cannabinoids)
Study: NCT03442088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
Study: NCT04221360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-375
Description: Test drug, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-375
Description: Test drug, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D390
Description: Reference drug, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D390
Description: Reference drug, QD, PO
Study: NCT05781022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic repair of iatrogenic esophageal perforation
Description: For patients in EG, we began with assessment of the site \& size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis
Study: NCT02187003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
Study: NCT02460432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting metal Stent
Description: Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered Metal Stent
Description: Insertion of ComVi Biliary Covered Stent using ERCP
Study: NCT05128266

Intervention type: PROCEDURE
Intervention: Endodontical Retreatment
Description: 1. Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~2. Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique.
Study: NCT00028262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystagon
Study: NCT01979523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04137107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01979523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprosertib
Description: Given PO
Study: NCT01038102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PUFA Diet
Description: Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SFA diet
Description: Diet high in saturated fat (15E%)
Study: NCT02807831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive functions training
Description: Daily training of executive functions via activities to develop auto-regulation, attention and memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language skills training
Description: Daily training of language skills via activities to develop phonological awareness and vocabulary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular school curriculum
Description: Ministry of Education national school curriculum.
Study: NCT01901042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control patients will receive sachets containing maltodextrin
Study: NCT03602716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS
Description: HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.
Study: NCT00503347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
Study: NCT00459719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus modified-release
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study: NCT04192890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal irreversible electroporation of the prostate cancer
Description: Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
Study: NCT03621436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRVD Therapy
Description: A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.
Study: NCT02591641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-shear mattress overlay
Description: A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-shear mattress overlay
Description: A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard ambulance stretcher mattress

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard ambulance stretcher mattress
Study: NCT04137107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT02185560

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients treated by Physician with Nexavar under approved local prescriptions
Study: NCT03366116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aza-TdC
Description: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to hypermethylation and silencing of tumor suppressor genes. Aza-TdC offers an improvement over traditional DNMT inhibitors via higher incorporation into DNA and lower cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to yield inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
Study: NCT00324805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT04351009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node mapping
Description: Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
Study: NCT02105376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal Nerve Stimulation (TNS)
Description: Trigeminal Nerve Stimulation (TNS)